Jason Zhang

Jason Zhang is a biopharmaceutical executive and co-founder and CEO of Zipcode Bio, a startup developing the next generation of nucleic acid applications. They are a leader in developing transformative solutions for patients with high unmet needs and have extensive experience in drug research and development, moving drug candidates into clinical trials across liver, neuromuscular, neurology, oncology, immunology and infectious diseases, with modalities including AAV gene therapy, oligos, vaccines, mRNAs, antibodies, and small molecules. Their past roles included CSO and co-founder at RVAC Medicines (2021–2023) and Vice President at Luye Pharma Group (2019–2020), with prior leadership at Luye GeneLeap Bio, Sanofi, and Wave Life Sciences. They earned a Ph.D. in Biology from New York University (2003–2008) and a Ph.D. in Chemistry from Peking Union Medical College (1998–2000), and completed an executive program at UC Berkeley's Haas School of Business; they also completed a NIBR presidential postdoc in Cancer Biology at Harvard University (2008–2010) and were a Visiting Fellow at the University of Oxford (2015–2016).